Laurie Orme, MD
Pediatrics · Edmond, OKNPI 1114925302
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,255 and has fallen 81.7% since, to $229 in 2025. Among pediatrics clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$727
- GSK$674
- AstraZeneca$561
- Novo Nordisk$439
- Lilly USA, LLC$431
- Takeda Pharmaceuticals U.S.A., Inc.$397
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,781100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 44 | $727 |
| GSK | 55 | $674 |
| AstraZeneca(2 entities) | 38 | $561 |
| Novo Nordisk | 35 | $439 |
| Lilly USA, LLC | 33 | $431 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $397 |
| Boehringer Ingelheim | 22 | $306 |
| AbbVie(2 entities) | 12 | $191 |
| Merck | 13 | $190 |
| Shire North American Group Inc | 9 | $146 |
| Sumitomo Pharma America, Inc. | 5 | $112 |
| Sanofi-aventis U.S. LLC | 6 | $89 |
| Exact Sciences | 4 | $76 |
| Amgen | 3 | $50 |
| Bayer | 2 | $45 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Abbott | 2 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Currax Pharmaceuticals LLC | 2 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Vyera Pharmaceuticals, LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
How this compares
$4,781 in reported general payments places this provider in the 95th percentile of 568 pediatrics providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 82 | $93,562 |
| JardianceEmpagliflozin | 66 | $58,331 |
| TrulicityDulaglutide | 32 | $38,767 |
| EliquisApixaban | 37 | $38,580 |
| JanuviaSitagliptin Phosphate | 41 | $34,904 |
| OzempicSemaglutide | 14 | $26,877 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $25,454 |
| FarxigaDapagliflozin Propanediol | 12 | $14,500 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $13,793 |
| XareltoRivaroxaban | 14 | $11,925 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $10,264 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $6,544 |
| Atorvastatin Calcium | 142 | $2,500 |
| Buprenorphine | 12 | $2,498 |
| SynthroidLevothyroxine Sodium | 27 | $2,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $431 | $132,328114 claims |
| Boehringer IngelheimJardiance | $306 | $58,33166 claims |
| PfizerEliquis | $727 | $38,58037 claims |
| MerckJanuvia | $190 | $34,90441 claims |
| Novo NordiskOzempic | $439 | $26,87714 claims |
| GSKTrelegy Ellipta | $674 | $25,45418 claims |
| AstraZenecaFarxiga | $561 | $14,50012 claims |
| AbbVieSynthroid | $191 | $2,23127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 568 pediatrics providers in Oklahoma.
Other pediatrics in Edmond
- Sabrina OlayEdmond$4K
- Jessica YocumEdmond$2K
- Katherine BrashearsEdmond$2K
- Stanley GroggTulsa$24K
- Scott MelsonOklahoma City$11K
- Angela ConradTulsa$6K
- Todd ColemanTulsa$5K
- Julie MayOklahoma City$5K
- Patrick DaleyTulsa$5K
- Rachel SpragueOklahoma City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.